Extended Data Fig. 10: Loss of ADAR1 overcomes multiple common mechanisms of resistance to immunotherapy in vivo.
From: Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade
a, Survival analysis corresponding to tumour volume curves from Fig. 5c depicting the effect of Adar1 deletion in B16 tumours in which Jak1 or B2m have been epistatically deleted. n = 5 animals per group; data are representative of two independent experiments. b, Tumour volume curves in control (grey) and Adar1-null (red) B16 tumour cells epistatically deleted for H2k1, Jak2 and Nlrc5 and treated with GVAX and anti-PD-1 as indicated (n = 5 animals per group). c, Survival analysis corresponding to the tumour volume curves depicted in b. d, Additional TME characterization of control and Adar1-null B16 tumour cells epistatically deleted for Jak1 and B2m as indicated (n = 5 mice per group). Data in d and all tumour volume curves assessed with two-sided Student’s t-test; all survival curves assessed with log-rank test, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
